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Chris Roberts, PhD, and Myfanwy Lloyd-Jones, DPhil¶
Introduction: The burden of lung cancer is high for patients and
carers. Care after treatment may have the potential to impact on this.
We reviewed the published literature on follow-up strategies in-
tended to improve survival and quality of life.
Methods:We systematically reviewed studies comparing follow-up
regimes in lung cancer. Primary outcomes were overall survival
(comparing more intensive versus less intensive follow-up) and
survival comparing symptomatic with asymptomatic recurrence.
Quality of life was identified as a secondary outcome measure.
Hazard ratios (HRs) and 95% confidence intervals from eligible
studies were synthesized.
Results: Nine studies that examined the role of more intensive
follow-up for patients with lung cancer were included (eight obser-
vational studies and one randomized controlled trial). The studies of
curative resection included patients with non-small cell lung cancer
Stages I to III disease, and studies of palliative treatment follow-up
included limited and extensive stage patients with small cell lung
cancer. A total of 1669 patients were included in the studies.
Follow-up programs were heterogeneous and multifaceted. A non-
significant trend for intensive follow-up to improve survival was
identified, for the curative intent treatment subgroup (HR: 0.83; 95%
confidence interval: 0.66–1.05). Asymptomatic recurrence was as-
sociated with increased survival, which was statistically significant
HR: 0.61 (0.50–0.74) (p  0.01); quality of life was only assessed
in one study.
Conclusions: This meta-analysis must be interpreted with caution
due to the potential for bias in the included studies: observed benefit
may be due to systematic differences in outcomes rather than
intervention effects. Some benefit was noted from intensive fol-
low-up strategies. More robust data, in the form of randomized
controlled trials, are needed to confirm these findings as the review
is based primarily on observational studies. Future research
should also include patient-centered outcomes to investigate the
impact of follow-up regimes on living with lung cancer and
psychosocial well-being.
Key Words: Lung cancer, Follow-up, Aftercare, Survival,
Survivorship.
(J Thorac Oncol. 2011;6: 1993–2004)
Lung cancer is the most commonly diagnosed cancer world-wide, with incidence rates continuing to increase in de-
veloping countries.1,2 Although survival in the first year has
improved (25% in 2001),3 5-year survival remains poor. The
reported purpose of follow-up is to manage toxicity of treat-
ment, detect disease recurrence, and instigate further treat-
ment/supportive care without delay.4 Follow-up has become
increasingly relevant with the availability of second- and
third-line treatments, which have resulted in improvements in
quality of life (QOL) and survival. Patients with lung cancer
have high levels of symptom burden,5 with uncontrolled
symptoms often presenting as clusters.6 Guidelines on fol-
low-up vary internationally (Table 1).
Concerns have been expressed about the effective-
ness of conventional physician-led hospital-based follow-
up, suggesting that it is ineffective at detecting recur-
rence,14 that earlier detection of recurrence does not
improve life expectancy,15 and that patients emotional
distress is inadequately identified and addressed.16 Alter-
native strategies include follow-up by primary care physi-
cians/general practitioners (GPs), nurses, the telephone,
and open-access clinics where patients are able to drop in
on demand.14,17–19
There is a paucity of evidence for different follow-up
strategies for patients with lung cancer and their cost-effec-
tiveness. An earlier systematic review was undertaken to
inform clinical guidelines for the follow-up of non-small cell
lung cancer (NSCLC), but this review did not meta-analyze
survival data or include QOL or patient satisfaction data.8 For
this reason, we undertook a systematic review and meta-
analysis of follow-up strategies for both small cell lung
cancer (SCLC) and NSCLC.
*School of Nursing, Midwifery and Social Work, Jean McFarlane Building,
University of Manchester, Manchester Academic Health Science Centre,
Manchester; †School of Health, University of Central Lancashire, Pres-
ton; ‡Sheffield Clinical Trials Research Unit, University of Sheffield,
Sheffield; §Department of Medical Oncology, The Christie NHS Foun-
dation Trust; ||Health Methodology Research Group, Jean McFarlane
Building, University of Manchester, Manchester Academic Health Sci-
ence Centre, Manchester; and ¶School of Health and Related Research
(ScHARR), University of Sheffield, Sheffield, United Kingdom.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Lynn Calman, PhD, School of Nursing, Mid-
wifery and Social Work, the University of Manchester, University Place,
Rm. 5.328, Oxford Road, Manchester M13 9PL, UK. E-mail:
lynn.calman@manchester.ac.uk
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0612-1993
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 1993
METHODS
A review protocol is available from the corresponding
author.
Search Strategy
We aimed to identify all literature related to follow-up
of patients with lung cancer. Searches were conducted in July
and August 2008. Initially no language, study/publication, or
date restrictions were applied. Relevant articles were identi-
fied and retrieved from Ovid Medline, Embase, PsycINFO,
CINAHL, and British Nursing Index. All databases held by
the Cochrane Library Issue 3, 2008, including Cochrane
Database of Systematic Reviews, Database of Abstracts of
Reviews of Effects, Cochrane Central Register of Controlled
Trials, Cochrane Database of Methodology Reviews, Health
Technology Assessment Database, and National Health Ser-
vice Economic Evaluation Database were searched. Elec-
tronic searches were supplemented by reviewing reference
lists for identified studies. Work in progress was searched for
using Current Controlled Trials, National Institutes of Health
clinical trials databases, and the National Research Register.
Only English language articles were included in the
analysis, together with one German article that contained
sufficient detail in the abstract and survival curves for inclu-
sion. The full search strategy is shown in Figure 1.
Inclusion and Exclusion Criteria
The population of interest for this review was patients
older than 18 years (with no upper age limit) who had been
treated for primary lung carcinoma and were in follow-up.
All lung cancer histological types, SCLC and NSCLC, were
included in the review. All treatment options, surgery, radio-
therapy, and chemotherapy (or, as is often the case, a com-
bination of these) were included. All stages of lung cancer
were included in the review.
In line with previous reviews and published guidance,
lung cancer follow-up is defined as care after treatment,
which is planned and multifaceted. For inclusion in the
TABLE 1. International Recommendations for Follow-Up After Curative Intent Treatment and Palliative Treatment for Lung Cancer
Guidelines Frequency Components
Follow-up after surgery or radical
radiotherapy with curative intent
ESMO7 6 mo for first 2 yr and every 12 mo thereafter (early
stage and locally advanced NSCLC)
History, physical examination, radiologic
ACCP8 6 mo for 2 yr then annually History, examination, imaging CT CXR
SIGN9 Follow-up developed locally, hospital follow-up
where hospital treatment or specialist advice is
still needed—or clinical trial ongoing—after
surgery initial follow-up by surgeon then local
follow-up
NICE10 All patients to be offered an initial specialist follow-
up appointment within 6 wk of completing
treatment to discuss ongoing care. Offer regular
appointments thereafter, rather than relying on
patients requesting appointments when they
experience symptoms
Offer protocol-driven follow-up led by a lung cancer
clinical nurse specialist as an option for patients
with a life expectancy of more than 3 mo
Ensure that patients know how to contact the lung
cancer clinical nurse specialist involved in their
care between their scheduled hospital visits
International consensus statement11 3 mo for the first 2 yr, then every 6 mo up to 5 yr History, clinical examination, and chest x-ray-CT
scans and other tests should be performed in case
of clinical indication
Smoking cessation
Follow-up after palliative treatment
ESMO12,13 No evidence that the follow-up of asymptomatic
patients is needed (SCLC)
Specific examinations as clinically needed
Close follow-up is advised (metastatic NSCLC)
SIGN9 Follow-up developed locally, hospital follow-up
where hospital treatment or specialist advice is
still needed, or clinical trial ongoing
NICE10 All patients to be offered an initial specialist follow-
up appointment within 6 wk of completing
treatment to discuss ongoing care. Offer regular
appointments thereafter, rather than relying on
patients requesting appointments when they
experience symptoms
Offer protocol-driven follow-up led by a lung cancer
clinical nurse specialist as an option for patients
with a life expectancy of more than 3 mo
Ensure that patients know how to contact the lung
cancer clinical nurse specialist involved in their
care between their scheduled hospital visits
International consensus statement11 1–2 mo for the first 6 mo History, clinical examination, and chest x-ray-CT
scans and other tests should be performed in case
of clinical indication
Smoking cessation
CXR, chest x-ray; NSCLC, non-small cell lung cancer; CT, computed tomography; SCLC, small cell lung cancer.
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review, the primary focus of the study had to be multifaceted
follow-up interventions. Multifaceted programs were defined
as those that included multiple types of assessment, not just
individual types of imaging or tests, and ideally included
symptom management, education, health promotion (includ-
ing smoking cessation if appropriate), and psychosocial sup-
port. Control groups were defined within individual studies,
and no “standard” follow-up plan was common across stud-
ies, reflecting the variability in follow-up strategies in clinical
practice. Variability in programs could be defined by inten-
sity of follow-up; we compared more intensive with less
intensive follow-up.
Primary outcomes included overall survival and
asymptomatic survival. Secondary outcomes were time to
detection of recurrence, and change in self-reported QOL
from baseline (start of follow-up) to end of follow-up, or
death. Generic, disease-specific, and tumor site-specific
QOL measures were included if they measured QOL in a
standardized format and produced aggregate summary
scores. Both interview and self-completed formats for
either generic- or disease (or tumor)-specific measures
were included. Change in symptom experience/burden and
patient satisfaction was also included as an outcome if
measured by a validated instrument. Only studies that
reported at least one of the primary outcomes were in-
cluded. Because of limited reported data, cost was not
included as a formal outcome measure.
Although randomized controlled trials (RCTs) are
widely regarded as the most appropriate design to evaluate
efficacy of an intervention, a scoping review identified a
paucity of studies using this design. Therefore, we included
RCTs, quasiexperimental, and observational (case-control or
cohort) studies. This approach may potentially result in less
robust studies being used for the development of evidence but
provides the best evidence currently available in this under-
researched area.
Data Extraction and Quality Assessment
All abstracts were read, and studies meeting the inclu-
sion criteria were identified. Data extraction and quality
assessment were carried out by two reviewers (L.C. and
K.B.). Discrepancies were discussed to reach consensus. A
standardized form was developed to extract data from each
study, including design, inclusion criteria, baseline character-
istics of intervention and control groups, key aspects of study
quality, and results. Details of the intervention in treatment
and control (standard practice) groups were extracted, includ-
ing frequency of visits, investigations ordered, and examina-
tions conducted. Data on outcome measures were tabulated to
facilitate quantitative data synthesis. Data on quality included
evaluation of generalizability, reliability, validity, definition
validity, theoretical basis, and clinical versus statistical sig-
nificance.
Statistical Analysis
If more than one study had similar populations, inter-
ventions, and outcomes, the relevant data were statistically
synthesized. Time to event data were synthesized using
hazard ratios (HRs) and 95% confidence intervals (CIs).
1. exp Lung Neoplasms/ 
2. lung neoplasms.mp. 
3. lung cancer.mp. 
4. sclc.mp. or exp Carcinoma, Small Cell/ 
5. nsclc.mp. or Carcinoma, Non-Small-Cell Lung/ 
6. Carcinoma, Non-Small-Cell Lung/ 
7. carcinoma non small cell lung.mp.  
8. carcinoma small cell lung.mp.  
9. adenocarcinoma bronch$.mp.  
10. lung malig$.mp 
11. cancer.mp.
12. neoplas$.mp.  
13. tumour.mp.  
14. oncolo$.mp.
15. malignan$.mp 
16. lung.mp.  
17. pulmon$.mp 
18. bronch$.mp.
19. Follow-Up Studies/ or follow-up.mp. 
20. exp Patient Discharge/ or patients discharge.mp. 
21. surveillance.mp. 
22. recurrence.mp. 
23. cancer follow-up.mp.  
24. check up.mp. 
25. exp Outpatient Clinics, Hospital/ 
26. clinics.mp. 
27. follow-up.mp. 
28. 26 and 27 
29. hospital.mp. or exp Hospitals/ 
30. 27 and 29 
31. primary care.mp. or Primary Health Care/ 
32. 27 and 31 
33. special$.mp. 
34. 27 and 33 
35. consultant.mp. or exp Consultants/ 
36. 27 and 35 
37. nurse$.mp. or exp Nurses/ 
38. 27 and 37 
39. primary care.mp. or exp Primary Health Care/ 
40. 27 and 39 
41. Physicians, Family/ or Family Practice/ or gp.mp. 
42. 27 and 41 
43. general practitioner.mp. 
44. 27 and 43 
45. tumo$.mp.  
46. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
47. 11 or 12 or 13 or 14 or 15 or 45 
48. 16 or 17 or 18 
49. 47 and 48 
50. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 28 or 30 or    
       32 or 34 or 36 or 38 or 40 or 42 or 44 
51. 46 and 49 and 50 
FIGURE 1. Search strategy for Medline, Embase,
CINAHL, BNI, and PsycINFO on ovid web version
(last run on August 10, 2008).
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As summary statistics was not available in any of the
articles to allow direct calculation of the HR and CIs, HRs
were estimated using two of the methods presented by Tier-
ney et al.20 When the p value was reported, the HR and
variance were estimated using the p value (log rank, Mantel
Hansel, or Cox regression) and events in each arm observed–
expected. This was possible with 10 calculations. An Excel
spreadsheet developed by the MRC Clinical Trials Unit was
used to calculate the above statistics.21
When the p value was not reported, the HR was
calculated using survival curve data extracted from study
reports.20 The survival curve from a PDF file of the published
article was copied and imported into Image J software.22 The
curve was divided into time periods as suggested by Parmar
et al.23; no more than 20% of total events were included in
each time period, and time periods differed between each
study depending on event rate. An Excel spreadsheet was
used to calculate percentages in control and treatment arms
who were event free and numbers at risk in each arm. From
this curve data,21 variance, observed minus expected (O E)
values, and HR were calculated.
Minimum and maximum follow-up were estimated and
entered into the Excel file to estimate HR accurately. These
data were either identified directly from data reported or
estimated from the survival curve using methods suggested
by Tierney et al.20 This allowed censoring in the trial to be
accounted for, otherwise estimates of HR would be based on
too many patients.20 Tables 2 and 3 indicate what methods
were used to calculate the HR for each study outcome.
These data were then inputted into Cochrane Collabo-
ration Review Manager 4.2 software.32 The Peto odds ratio
(HR) was chosen as the effect measure and the Exp ((O/E)/
Var) statistical methods applied.33
A fixed effect model was used for the primary analysis;
this is an assumption when using the variation of the Peto
odds ratio for time to event data.33 Heterogeneity was inves-
tigated by examining the X2 and the I2 statistic.34
It was stated prospectively that subgroup analysis
would take place on the basis of treatment intent. Treatment
with curative intent and prognosis of early-stage NSCLC
populations are sufficiently different to not support a pooled
analysis with patients with advanced disease and palliative
treatment. Curative intent treatment included surgery alone or
multimodality treatment—a combination of chemotherapy,
radiotherapy, and surgery with curative intent. Palliative
treatment included chemotherapy and radiotherapy.
The reporting of this meta-analysis is in accordance
with the PRISMA statement for reporting systematic re-
views and meta-analyses of studies that evaluate health
care interventions.35
Role of the Funding Source
No funders were involved in study design; in the
collection, analysis, and interpretation of data; in the writing
of the report; or in the decision to submit the report for
publication.
RESULTS
Trial Flow
Electronic and hand searches identified 20,627 cita-
tions, resulting from the high sensitivity of the search. Fol-
low-up search terms lack specificity, and a large number of
citations were easily excluded when screening the title. An
initial screen of the electronic search resulted in the selection of
203 abstracts for further analysis. Of these, 141 were excluded
and 62 were identified for a full text review. Forty-six of the 62
were excluded because they did not meet the entry criteria.
Sixteen studies had outcomes relevant to the study and were
reassessed to identify the primary outcome and whether suffi-
cient data were available for inclusion in the statistical analysis;
nine were finally included in the review. Reasons for exclu-
sions36–40 and trial flow are presented in Figure 2.
Study Characteristics
Four studies were based in North America,14,24,28,31
three in Europe,25,29,30 one in South America,27 and one in
Japan.26 Five comparative cohort studies examined survival
after follow-up regimes of varying intensity.24,28,26,27,29 Two
single cohort studies of follow-up programs compared sur-
vival after symptomatic or asymptomatic recurrence.31,30 One
RCT compared survival between nurse-led and conventional
follow-up care.25 One cohort study compared survival be-
tween follow-up by GPs and conventional specialist led
hospital care31 (Tables 2 and 3).
Follow-Up Programs
Details of the follow-up programs implemented are
given in Tables 2 and 3. It is important to note that in some
studies the more intensive arm resembled standard or routine
practice when compared with international guidelines, but
these programs were compared with less intensive programs
(e.g., regular versus no standardized follow-up).29 Higher inten-
sity programs had more frequent imaging carried out at set time
points. The exceptions to this were the studies by Moore et al.,25
where intensive follow-up included clinic visits and contact with
patients but not increased imaging or extra clinical procedures,
and Gilbert et al.14 where standard follow-up was compared with
detection by the family practitioner.
Characteristics of Participants
A total of 1669 patients were included in the studies.
Study sizes ranged from 75 to 358. In eight studies that
reported gender, 67% of participants were men (n  1487).
An additional study (n  182) did not provide numbers but
reported that most participants were men.28 The overall me-
dian age range was 58 to 68 years.
The studies of follow-up care after potentially curative
resection (NSCLC) included patients with stages I to III
disease, reflecting the stage of disease deemed appropriate for
curative intent treatment. The study investigating follow-up
after palliative treatment included limited and extensive stage
patients with SCLC. One study (Moore et al.25) included
patients with a mix of stages and treatments but the minority
of included patients (23%) had stages I to IIIa disease.
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Quality of the Included Studies
Seven studies had retrospective database cohort de-
signs.14,24,26–29,31 These retrospective studies are particularly
prone to bias as they rely on data collected for another
purpose.41 The prospective cohort study was relatively ro-
bust, reporting no nonresponses and adherence to the inter-
vention of 92% for chest x-rays, 83% for computed tomog-
raphy (CT) scans, and 93% for fiberoptic bronchoscopy.30
The RCT failed to report how the randomization sequence
was generated or whether treatment allocation was con-
cealed.25
Overall Survival—Intensive versus Nonintensive
Follow-Up
Six studies examined survival in patients with lung
cancer, comparing more intensive versus less intensive fol-
low-up programs (Figure 3). In the curative intent subgroup,
the general trend for improvement in survival favored more
intensive follow-up: HR: 0.83 (0.66–1.05), but this was not
statistically significant (p  0.13). Between-study heteroge-
neity was low.
Two further studies reported this data: the RCT by
Moore et al.25 with a mix of patients including all stages and
treatment regimes and a nurse-led follow-up plan; and the
retrospective design presented by Sugiyama et al.,26 including
patients with SCLC who had a response to first-line chemo-
therapy. These two studies were sufficiently different, in
terms of the sample and design, that pooling the findings was
not useful; heterogeneity was high (I2  65%) when they
were pooled.
Only one article30 reported a Cox model adjusted for
treatment. Some factors were found to predict survival re-
gardless of treatment (curative, palliative, or best supportive
care). Absence of symptoms, female sex, performance status
of 2 or less, and age 61 years were found to be favorable
prognostic factors.
Survival—Asymptomatic versus Symptomatic
Recurrence
High rates of relapse (between 21% and 71%) were
reported even when curative treatment was intended, and pa-
tients were as likely to have a relapse detected with an unsched-
uled consultation as with routine appointments.14,24,30,27
In the curative intent subgroup, all the studies found
that asymptomatic recurrence was associated with a signifi-
cantly longer survival time: HR: 0.61 (0.50–0.74) (p 0.01),
with a low level of heterogeneity (Figure 4). No included
palliative treatment studies presented this data. The study
with a population of patients with SCLC, who responded to
first-line chemotherapy, reported a recurrence rate of 91%.26
Assessment of Secondary Outcome Measures
Time to Detection of Recurrence—Intensive versus
Nonintensive Follow-Up
Three studies24,26,27 reported time to detection of recur-
rence with more intensive versus less intensive follow-up.
Data were pooled for two studies,24,27 which reported time to
disease progression after curative treatment. Intensive versus
less intensive follow-up had no impact on time to detection ofTA
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recurrence (HR: 0.85, CI: 0.50–1.42, p  0.52) with low
heterogeneity (I2  0%).
Sugiyama et al.,26 reporting on patients with SCLC
after chemotherapy, found no difference between the more
intensive and the less intensive follow-up program (HR: 0.98,
CI: 0.65–1.48). This finding was not significant. Asymptom-
atic recurrence was detected more frequently in the intensive
arm. The included studies indicate little or no difference in
FIGURE 2. Trial flow.
FIGURE 3. Overall survival—more intensive vs. less intensive follow-up (NSCLC and SCLC, and advanced NSCLC). NSCLC,
non-small cell lung cancer; SCLC, small cell lung cancer.
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how patients were treated regardless of whether they had
asymptomatic or symptomatic recurrence.
Quality of Life
Only one study reported QOL outcomes.25 QOL was
assessed at baseline (end of treatment) and at monthly inter-
vals using the European Organisation for Research and Treat-
ment of Cancer core questionnaire and lung cancer specific
module.42 This questionnaire has five functional scales (phys-
ical, role, emotional, cognitive, and social), three symptom
scales (fatigue, nausea and vomiting, and pain), and a global
health status/QOL scale. At 3 months, patients on the nurse-
led arm of the trial rated their dyspnoea as less severe (p 
0.03) than patients on the conventional follow-up arm. No
other significant differences were found at this time point or
at 6 months. At 12 months, compared with the conventional
care group, patients in the nurse-led arm had improved scores
for emotional functioning (p  0.03) and less peripheral
neuropathy (p  0.05).
DISCUSSION
There is little robust evidence on which to base the
follow-up of patients with lung cancer. Despite heterogeneity
of patient and follow-up, it was felt useful to synthesize
evidence using meta-analysis techniques to identify trends in
published data to guide clinical practice. There is a trend for
more intensive follow-up to improve survival of patients with
lung cancer, although the data do not reach statistical signif-
icance. This trend is less convincing in the palliative treat-
ment subgroup than the curative intent subgroup. This may
not count as sufficient evidence to change practice or justify
the potential increased cost of intensive follow-up in routine
care.
Three included studies reported an economic evaluation
of more intensive follow-up.14,25,27 Although cost-effective-
ness was not originally considered in the review as an
outcome measure, the findings from the economic evalua-
tions warrant discussion given the current economic climate.
Standard reimbursements (or National Health Service costs in
the United Kingdom) for consultations and the associated
costs of any tests or investigations were used to estimate cost;
treatment costs were excluded. Two retrospective studies14,27
estimated that there would be a reduction in cost of approx-
imately 70% with patient-led symptom-oriented follow-up
versus more intensive prescribed follow-up. The RCT by
Moore et al.25 did not identify a significant increase in costs
for the nurse-led arm, but the cost of the intervention was not
included, and they note that sample size may not have been
sufficient to detect a difference.
A previous review of 10 published articles retrospec-
tively estimated the cost of follow-up (not including retreat-
ment) after potentially curative treatment.43 Regimes using
bronchoscopy and CT scanning were at the higher end of the
cost spectrum. When the costs of retreatment (further surgical
intervention) were included,44 the cost per life year gained
increased to $56,000 compared with the acceptable threshold
set in the United Kingdom (£20–30,00045) and the United
States (reported in 2002 as $50,000 per life year gained).44
There are no contemporary published economic evaluations
that take into account recent changes in imaging technology,
such as positron emission tomography (PET) scanning, and
targeted treatment, and their subsequent impact on resource
utilization and QOL at follow-up.
Prognosis is poor for the majority of patients with lung
cancer with recurrence or disease progression, and small
improvements in survival may be clinically meaningful, even
if not statistically significant. Virgo et al.28 report that, al-
though the difference in survival between intensive and
nonintensive follow-up in NSCLC was not statistically sig-
nificant, patients in the intensive group had a survival advan-
tage of 0.53 years. Large prospective studies are required to
be sensitive to these small differences.
It is important to know whether follow-up regimes can
identify patients who are asymptomatic at recurrence, assum-
ing that by the time patients have symptoms, the recurrence is
further advanced and, therefore, less amenable to treatment.
There is a trend, but no clear evidence, that intensive fol-
low-up reduces time to detection of recurrence.
Identification of asymptomatic recurrence seemed ben-
eficial to patients treated with curative intent. Although this
may be due in part to the opportunity for early intervention to
treat recurrence, lead time bias may be a factor in the
(apparently) extended survival of asymptomatic patients.
This improved survival was not reflected in statistically
significant differences between follow-up regimes. Studies
had small sample sizes, and data were derived from retro-
spective database studies. The included studies are likely to
be underpowered to show difference in survival. Intensive
FIGURE 4. Survival—asymptomatic vs. symptomatic recurrence (NSCLC after curative intent treatment). NSCLC, non-small
cell lung cancer.
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programs may not be sensitive enough to identify sufficient
patients whose recurrence is asymptomatic to make a differ-
ence to overall survival. This may be due to the natural
history of lung cancer as there is only a short period in which
recurrence is asymptomatic, in contrast to other types of
cancer such as cervical cancer where the lead time between
asymptomatic disease and symptoms can be significant.
The absence of any statistical difference in time to
recurrence when comparing more intensive and less intensive
follow-up may be explained by deviation from scheduled
follow-up appointments. In the study by Benamore et al.,24
two thirds of patients with relapse (n  44) sought medical
attention before a scheduled appointment, thus diluting the
effect of intensive follow-up. This makes it difficult to make
recommendations about the timing of follow-up appoint-
ments. It may be more important to give patients information
about what symptoms would necessitate an earlier consulta-
tion. Sugiyama et al.26 report that although there was no
statistical difference in time to recurrence with intensive
follow-up, the median time to detection of initial occurrence
was 5 months in the intensive arm and 7 months in the
nonintensive arm. This may have clinical importance, partic-
ularly as asymptomatic recurrences were detected more fre-
quently in the intensive arm (p  0.03).
Whether patients had asymptomatic or symptomatic
recurrence did not influence what treatment they were sub-
sequently offered, reflecting other published research.46,47
Regardless of what therapy was instituted after recurrence,
survival was poor. Nevertheless, this may change with new
targeted agents.
Caution should be used when meta-analyzing observa-
tional studies as confounding and selection bias can cast
doubt on findings: sources of bias and heterogeneity should
be carefully examined and, although the statistical combina-
tion of observational studies should not be abandoned alto-
gether, it should not be a prominent component of review.48
We have described issues of heterogeneity carefully in the
limitations section to allow readers to make a judgment about
the pooling of results. Observational studies are more prone
to bias than experimental studies, leading to systematic dif-
ferences in outcomes that are not due to intervention effects.
As a result, observational studies tend to report larger treat-
ment effects than RCTs.49 Only one included article at-
tempted to address confounding variables such as age, treat-
ment, performance status, and disease stage. Survival may be
influenced by these additional factors.
Based on these findings, a case may be made for
identifying asymptomatic recurrence after curative treatment.
Treatment outcomes in patients with advanced disease are
poor, and earlier detection of recurrence or progression may
make little difference. Nevertheless, the potential of second-
and third-line palliative and targeted treatments to improve
survival may not have been captured in these included stud-
ies. For this reason, identifying patients with asymptomatic
recurrence or progression after palliative treatment may be
increasingly important.
It is important not to abandon structured follow-up
programs on the basis of this survival analysis. Follow-up
serves other important functions. There are few reported data
on the impact of follow-up on symptom control, symptom
avoidance, or QOL. Prediagnosis QOL is an important prog-
nostic factor for patients with lung cancer,50,51 and early
evidence suggests that there may be potential in investigating
whether improved QOL after treatment improves survival.52 By
primarily focusing on survival, the literature may be missing the
valuable contribution that follow-up makes for the support of
patients and their families. With the increasing importance of
cancer survivorship outcomes, it may be important to include
these in any future evaluation of aftercare.53
The preferences of patients with lung cancer for fol-
low-up have recently been explored.54 Patients viewed fol-
low-up favorably, citing reassurance as a positive outcome of
the follow-up visit. Patients reported that they preferred to be
seen by medical staff based in a hospital clinic, with nurse-led
care as an acceptable option; primary care physicians (GPs)
and telephone follow-up were viewed less favorably.54
Implications for Future Research
This meta-analysis highlights that there is scope for
further research in lung cancer follow-up, particularly in
SCLC. There is scant evidence for follow-up of patients after
different treatment regimes.10 Robust RCTs are necessary to
develop convincing evidence for follow-up interventions. It is
unlikely that one follow-up program will be suitable for all
patients and investigating alternative programs such as nurse-
led, intensive, and primary care options would allow for
patient and clinician choice. One ongoing trial with postop-
erative patients with NSCLC in France is comparing minimal
follow-up (chest x-ray and clinical examination) with a more
intensive program.55
It is important that future research includes well-
defined patient groups, given the distinct differences in prog-
nosis and focus of follow-up interventions. Patients treated
with curative intent could gain a survival benefit from early
diagnosis of recurrence, if more effective treatments are
available in the future. Patients with advanced disease could
benefit from early commencement of supportive care with the
potential for improving QOL and possibly survival.52 Identi-
fying and targeting subgroups who might benefit from inten-
sive or other models of follow-up is of primary importance.
For example, there is evidence that fluorodeoxyglucose-
position emission tomography CT can identify progression
amenable to potentially radical treatment in a small propor-
tion of patients (3%) and could be targeted at asymptomatic
patients.56 A further economic evaluation using a decision
analytic Markov model highlighted PET-CT as cost-effective
(particularly for asymptomatic patients) in the follow-up of
patients with NSCLC.57
Identifying an appropriate primary end point for studies
of follow-up interventions for patients with lung cancer is
imperative. It is difficult to measure, without robust studies, a
statistically significant improvement in survival that can be
attributed to follow-up programs. Nevertheless, for some pa-
tients, any improvement in survival, even if it is measured in
weeks, is the most important clinical outcome. Follow-up should
be multifaceted and encompass QOL/survivorship issues, in-
cluding rehabilitation, as well as a focus on survival. Patient-
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orientated outcomes defined by patients, such as QOL and
satisfaction, may be relevant primary outcomes of studies.
If the aim of follow-up programs is to identify early
recurrence, it would be important to investigate the impact
that this might have on patients’ psychological well-being as
patients look to follow-up appointments for hope, reassur-
ance, and “good news.”54 More work is needed to give
patients an evidence-based message about what follow-up
achieves for them to make choices about their aftercare. The
balance between psychosocial support and the survival ad-
vantage that more intensive, investigation-driven, follow-up
may bring needs to be considered.
Limitations
This meta-analysis of predominately observational
studies has to be interpreted with caution; results were pooled
only where there was sufficient clinical homogeneity. Nev-
ertheless, this may still be considered inappropriate for eval-
uating clinical effectiveness.49
An important limitation of this meta-analysis was the
heterogeneity of the studies. There was heterogeneity in study
design and in follow-up interventions, as described previ-
ously, and in populations and in the calculation of survival.
The study samples were heterogeneous: for example, in the
curative intent group, the addition of the study by Benamore
et al.24 increased heterogeneity by including patients with
locally advanced disease stage IIIA and stage IIIB who will
have a poorer prognosis. Another source of heterogeneity was
the date from which survival analysis was calculated. This
was not reported in two retrospective studies, but, when
reported, it was taken from the first encounter with health
care after the completion of treatment. Because of the vari-
ability in follow-up regimes, this date differed from 1 week to
3 months posttreatment (Table 2).
Nevertheless, where data were pooled, heterogeneity in
the analysis I2 was 0%. (Figures 3 and 4) suggesting that the
effect size remained relatively constant despite the underlying
clinical and methodological heterogeneity.
The interpretation of findings is complicated by issues
of internal and external validity. Particular threats to the
internal validity of the studies included in this analysis are
selection bias through lack of randomization and lead time
bias. Only English language studies were included. The role
of confounding variables is addressed in one study only;
survival may be influenced by confounding factors, but few
data are reported, which would allow exploration of this
hypothesis.
Conclusions and Recommendations
Current international clinical guidelines for NSCLC
and SCLC are informed by expert opinion; limited empirical
evidence is available (particularly for patients after palliative
treatment) to inform clinical management of patients. Guide-
lines recommend regular follow-up. This review has estab-
lished no evidence that would contradict this, and guidelines
should be adhered to, so that regular contact with patients and
carers can be maintained and further treatment and symptom
management instigated if necessary.
Any future research should include patient- and carer-
centered outcomes such as QOL and satisfaction to investi-
gate the impact of follow-up on living with lung cancer and
psychosocial well-being. Further research is warranted to
understand patients’ views of more intensive or invasive
follow-up programs or those using sophisticated scanning
techniques such as fluorodeoxyglucose-position emission to-
mography CT. False positives or early, asymptomatic, diag-
nosis of recurrence when this does not improve survival may
impact on QOL.
Alternative, innovative, approaches to follow-up
should be developed to cater for different disease subgroups
and patient choice. These programs should be evaluated
through robustly designed RCTs.
ACKNOWLEDGMENTS
Supported by a Medical Research Council (MRC) Spe-
cial Training Fellowship in Health Services Research
(G0601695) (awarded to L.C.).
Contributors: L.C. and M.L.-J. participated in the con-
ception and design of the study, interpretation, and analysis
of data. K.B. participated in data extraction and interpreta-
tion of data. D.H. participated in the design of the study and
analysis of data. C.R. and P.L. participated in interpretation
of data. All authors participated in the writing of the report
and approved the final version.
REFERENCES
1. World Health Organization IAfRoC. World Cancer Report. Lyon,
France: IARC Press, 2003.
2. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest 2007;
132(Suppl 3):29S–55S.
3. Coleman M, Rachet B, Woods LM, et al. Trends and socioeconomic
inequalities in cancer survival in England and Wales up to 2001. Br J
Cancer 2004;90:1367–1371.
4. Colice GL, Rubins J, Unger M, American College of Chest Physicians.
Follow-up and surveillance of the lung cancer patient following cura-
tive-intent therapy. Chest 2003;123(Suppl 1):272S–283S.
5. Vainio A, Auvinen A, with members of the Symptom Prevalence
Group. Prevalence of symptoms among patients with advanced can-
cer: an international collaborative study. J Pain Symptom Manage
1996;12:3–10.
6. Cooley ME. Symptoms in adults with lung cancer: a systematic research
review. J Pain Symptom Manage 2008;19:137–153.
7. Crino L, Weder W, van Meerbeeck J, et al, On behalf of the ESMO
Guidelines Working Group. Early stage and locally advanced (non-
metastatic) non-small-cell lung cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;
21(Suppl 5):v103–v115.
8. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung
cancer patient following curative intent therapy: ACCP evidence-based
clinical practice guidelines (2nd edition). Chest 2007;132:355S–367S.
9. Scottish Intercollegiate Guidelines Network. Management of Patients
with Lung Cancer, 80th Ed. Edinburgh: Scottish Intercollegiate Guide-
lines Network, 2005.
10. National Institute for Health and Clinical Excellence. The Diagnosis and
Treatment of Lung Cancer. London: National Institute for Health and
Clinical Excellence, 2011.
11. Saunders M, Sculier JP, Ball D, et al. Consensus: the follow-up of the
treated patient. Lung Cancer 2003;42(Suppl 1):S17–S19.
12. Sorensen M, Pijls-Johannesma M, Felip E, On behalf of the ESMO
Guidelines Working Group. Small-cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2010;21(Suppl 5):v120–v125.
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 Survival Benefits from Follow-Up
Copyright © 2011 by the International Association for the Study of Lung Cancer 2003
13. D’Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell lung
cancer: ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol 2010;21(Suppl 5):v116–v119.
14. Gilbert S, Reid KR, Lam MY, et al. Who should follow up lung cancer
patients after operation? Ann Thorac Surg 2000;69:1696–1700.
15. Smith T. Evidence-based follow-up of lung cancer patients. Semin Oncol
2003;30:361–368.
16. Hopwood P, Stephens RJ, Hopwood P, et al. Depression in patients with
lung cancer: prevalence and risk factors derived from quality-of-life
data. J Clin Oncol 2000;18:893–903.
17. Cox K, Wilson E. Follow-up for people with cancer: nurse-led services
and telephone interventions. J Adv Nurs 2003;43:51–61.
18. Adlard JW, Joseph J, Brammer CV, et al. Open access follow-up for
lung cancer: patient and staff satisfaction. Clin Oncol (R Coll Radiol)
2001;13:404–408.
19. Beaver K, Tysver-Robinson D, Campbell M, et al. Comparing hospital
and telephone follow-up after treatment for breast cancer: randomised
equivalence trial. BMJ 2009;338:a3147.
20. Tierney J, Stewart L, Ghersi D, et al. Practical methods for incorporating
summary time-to-event data into meta analysis. Trials 2007;8:16.
21. Tierney J, Stewart L, Ghersi D, et al. Practical Methods for Incorporating
Summary Time-to-Event Data into Meta Analysis (Supplementary Spread-
sheet). Available at: http://www.biomedcentral.com/content/supplementary/
1745-6215-8-16-S1.xls. Accessed June 2, 2011.
22. Rasbond W. ImageJ 1.40g. Available at: http://rsbweb.nih.gov/ij/index.
html, 2008. Accessed July 28, 2011.
23. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform
meta-analyses of the published literature for survival endpoints. Stat
Med 1988;17:2815–2844.
24. Benamore R, Shepherd FA, Leighl N, et al. Does intensive follow-up
alter outcome in patients with advanced lung cancer? J Thorac Oncol
2007;2:273–281.
25. Moore S, Corner J, Haviland J, et al. Nurse led follow up and conven-
tional medical follow up in management of patients with lung cancer:
randomised trial. BMJ 2002;325:1145–1147.
26. Sugiyama T, Hirose T, Hosaka T, et al. Effectiveness of intensive
follow-up after response in patients with small cell lung cancer. Lung
Cancer 2008;59:255–261.
27. Younes RN, Gross JL, Deheinzelin D, et al. Follow-up in lung cancer:
how often and for what purpose? Chest 1999;115:1494–1499.
28. Virgo KS, McKirgan LW, Caputo MC, et al. Post-treatment manage-
ment options for patients with lung cancer. Ann Surg 1995;222:700–
710.
29. Zieren HU, Muller JM, Petermann D, et al. The effectiveness of
standardized follow-up studies after resection of non-small cell bron-
chial carcinoma. Langenbecks Archiv fur Chirurgie 1994;379:299–306.
30. Westeel V, Choma D, Clement F, et al. Relevance of an intensive
postoperative follow-up after surgery for non-small cell lung cancer. Ann
Thorac Surg 2000;70:1185–1190.
31. Walsh GL, O’Connor M, Willis KM, et al. Is follow-up of lung cancer
patients after resection medically indicated and cost-effective? Ann
Thorac Surg 1995;60:1563–1570; discussion 1570–1572.
32. Review Manager (RevMan) Computer Program, Version 4.2. Copenha-
gen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2006.
33. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of
Interventions, Version 5.0. Availble at: http://www.cochranehandbook.org,
2008. Accessed July 28, 2011.
34. Fletcher J. What is heterogeneity and is it important? BMJ 2007;334:
94–96.
35. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
healthcare interventions: explanation and elaboration. BMJ 2009;339:
b2700.
36. Ataman OU, Barrett A, Filleron T, et al, ESTRO-REACT Group.
Optimization of follow-up timing from study of patterns of first failure
after primary treatment. An example from patients with NSCLC: a study
of the REACT working group of ESTRO. Radiother Oncol 2006;78:
95–100.
37. Bell N, Davison V, Peat M. Nurse and physiotherapy led follow-up for
lung cancer patients after surgery. Cancer Nurs Pract 2006;5:29–33.
38. McCorkle R, Benoliel JQ, Donaldson G, et al. A randomized clinical
trial of home nursing care for lung cancer patients. Cancer 1989;64:
1375–1382.
39. Kim DJ, Lee JG, Lee CY, et al. Long-term survival following pneumo-
nectomy for non-small cell lung cancer: clinical implications for fol-
low-up care. Chest 2007;132:178–184.
40. Nelemans FA, Nelemans FA. Follow-up examinations after operation
for lung cancer. Lancet 1973;2:206–207.
41. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective
database studies—report of the ISPOR task force on retrospective
databases. Value Health 2003;6:90–97.
42. Aaronson N, Ahmedzai S, Bergman B. The European Organisation for
Research and Treatment of Cancer QLQ30: a quality of life instrument
for use in international clinical trials in oncology. J Natl Cancer Inst
1993;85:365–376.
43. Virgo KS, Naunheim KS, McKirgan LW, et al. Cost of patient follow-up
after potentially curative lung cancer treatment. J Thorac Cardiovasc
Surg 1996;112:356–363.
44. Egermann U, Jaeggi K, Habicht JM, et al. Regular follow-up after
curative resection of nonsmall cell lung cancer: a real benefit for
patients? Eur Respir J 2002;19:464–468.
45. National Institute of Health and Clinical Excellence. Measuring
Effectiveness and Cost Effectiveness: the QALY. Available at: http://
www.nice.org.uk/newsroom/features/measingeffectivenessandcost
effectivenesstheqaly.jsp, 2008. Accessed July 28, 2011.
46. Pairolero P, Williams D, Bergstrahl E, et al. Postsurgical stage I
bronchogenic carcinoma: morbid implications of recurrent disease. Ann
Thorac Surg 1984;38:331–336.
47. Sheilds TW, Humphrey E, Higgins GA, et al. Long-term survivors after
resection of lung carcinoma. J Thorac Cardiovasc Surg 1978;76:439–
445.
48. Egger M, Schneider M, Davey Smith G. Meta-analysis spurious preci-
sion? Meta analysis of observational studies. BMJ 1998;316:140–144.
49. Pocock S, Elbourne D. Randomized trials or observational tribulations.
N Engl J Med 2000;342:1907–1909.
50. Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer
patients: as an important prognostic factor. Lung Cancer 2001;31:233–
240.
51. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a
prognostic indicator of survival: a meta-analysis of individual patient
data from EORTC clinical trials. Lancet Oncol 2009;10:865–871.
52. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for
patients with metastatic non small-cell lung cancer. N Engl J Med
2010;363:733–742.
53. Aziz NM. Cancer survivorship research: state of knowledge, challenges
and opportunities. Acta Oncol 2007;46:417–432.
54. Cox K, Wilson E, Heath L, et al. Preferences for follow-up after
treatment for lung cancer: assessing the nurse-led option. Cancer Nurs
2006;29:176–187.
55. Westeel VL. IFCT-0302 trial: randomised study comparing two fol-
low-up schedules in completely resected non-small cell lung cancer. Rev
Mal Respir 2007;24:645–652.
56. van Loon J, Grutters J, Wanders R, et al. Follow-up with 18FDG-
PET-CT after radical radiotherapy with or without chemotherapy allows
the detection of potentially curable progressive disease in non-small cell
lung cancer patients: a prospective study. Eur J Cancer 2009;45:588–
595.
57. van Loon J, Grutters JP, Wanders R, et al. 18FDG-PET-CT in the
follow-up of non-small cell lung cancer patients after radical radiother-
apy with or without chemotherapy: an economic evaluation. Eur J
Cancer 2010;46:110–119.
Calman et al. Journal of Thoracic Oncology • Volume 6, Number 12, December 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer2004
